Key points are not available for this paper at this time.
Introduction Novo Nordisk. E.W. Gregg: None. M.E. Pavkov: None. M. Arffman: Research Support; Roche Pharmaceuticals. H.M. Colhoun: Stock/Shareholder; Bayer Inc., Roche Pharmaceuticals. Research Support; Juvenile Diabetes Research Foundation (JDRF), IQVIA Inc., Diabetes UK, European Union. Advisory Panel; Novo Nordisk, Bayer Inc. K. Ha: None. T. Imamura: None. G. Jermendy: None. D. Kim: None. Z. Kiss: Employee; Merck Abbott, Amgen Inc., Gilead Sciences, Inc., Lilly Diabetes. Advisory Panel; Sanofi. Speaker's Bureau; Novo Nordisk. Advisory Panel; Novo Nordisk. S.J. McGurnaghan: None. Y. Nishioka: Speaker's Bureau; Sanofi, Daiichi Sankyo. S. Wild: Other Relationship; Novo Nordisk, Novo Nordisk Foundation. K. Winell: None. J.E. Shaw: Advisory Panel; GlaxoSmithKline plc. Research Support; AstraZeneca. Advisory Panel; AstraZeneca. Speaker's Bureau; AstraZeneca, Roche Diabetes Care, Boehringer-Ingelheim, Zuellig Pharma Holdings Pte. Ltd. Advisory Panel; Novo Nordisk. Speaker's Bureau; Roche Diagnostics. Advisory Panel; Roche Diagnostics, Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Abbott, Mylan. Speaker's Bureau; Sanofi. Funding Centers for Disease Control and Prevention, United States
Magliano et al. (Fri,) studied this question.